SOPHiA GENETICS, AstraZeneca and MSK Expand Access to cancer diagnostics

SOPHiA GENETICS, a cloud-native healthcare technology leader, has partnered with AstraZeneca to accelerate the global deployment of the liquid biopsy test, MSK-ACCESS®, powered by SOPHiA DDM™. This initiative aims to make liquid biopsy testing available at 20 healthcare institutions worldwide within 12 months. The liquid biopsy test, developed in collaboration with Memorial Sloan Kettering Cancer Center (MSK), offers a less invasive alternative to traditional biopsies by isolating circulating tumor DNA (ctDNA) from blood plasma. This approach is particularly valuable in situations where solid tumor testing is not feasible due to inadequate tissue or the invasiveness of the procedure.

SOPHiA GENETICS’ MSK-ACCESS® powered with SOPHiA DDM™ is a decentralized solution combining SOPHiA’s advanced analytics with MSK’s cancer genomics expertise. With this collaboration, the companies aim to expand access to this innovative diagnostic tool, which is already in use at 14 institutions worldwide, including major cancer centers and reference laboratories. A real-world evidence study is underway to evaluate the operational benefits of liquid biopsy testing, such as faster results and consistent high-quality data across different laboratory settings.

SOPHiA GENETICS and AstraZeneca began the landmark project in 2023, where SOPHiA CarePath™ identified a unique patient signature in lung cancer subpopulations, potentially guiding differential treatment approaches. AstraZeneca (AZ) deployed SOPHiA DDM’s HRD application across Spain in 2023. Following its success, a new partnership was announced to globally deploy MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDM™ in 2024, further enhancing cancer testing and treatment precision worldwide.

SOPHiA GENETICS delivered significant partnerships with Memorial Sloan Kettering Cancer Center, AstraZeneca, Boundless Bio, and Microsoft, among others.